Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health, Inc. (DE:82W)
NYSE:82W
82W Stock Chart & Stats
€13.47
-€0.66(-2.50%)
At close: 4:00 PM EST
€13.47
-€0.66(-2.50%)
Day’s Range― - ―
52-Week Range€13.15 - €65.36
Previous CloseN/A
Volume1.67K
Average Volume (3M)2.42K
Market Cap
€3.07B
Enterprise Value€4.25B
Total Cash (Recent Filing)€629.74M
Total Debt (Recent Filing)€1.12B
Price to Earnings (P/E)27.2
Beta2.08
Next Earnings
Feb 23, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding219,270,890
10 Day Avg. Volume3,878
30 Day Avg. Volume2,419
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)10.95
Price to Sales (P/S)3.54
P/FCF Ratio26.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€27.55Price Target Upside104.50% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Continuation Of Personalized CompoundingIf enforcement targets marketing rather than ingredient access, legitimate personalized compounding may continue at a smaller scale, preserving part of the GLP-1 revenue stream and mitigating downside.
Management Credibility And GuidanceRegaining management credibility and issuing credible guidance would rebuild investor confidence and support the firm's long-term opportunity.
Market Adoption And Marketing EffectivenessWeb traffic growth on the consumer site combined with a prior bold marketing push indicates sustained consumer adoption of compounded injectable GLP-1 products and supports demand potential.
Bears Say
Intellectual Property LitigationA patent infringement suit from a major manufacturer seeking damages and an injunction raises the prospect of costly legal awards and potential limits on selling disputed products.
Operational And Financial PressureSlowing core growth, margin headwinds, halted oral product sales, and uncertainty around repurposing planned capacity increase the likelihood of continued share pressure and operational disruption.
Regulatory Enforcement RiskRegulatory signals that restrict GLP-1 active ingredients and public naming by regulators create a material risk that access to core ingredients could be limited and a significant portion of compounding revenue could be eliminated.
Hims & Hers Health News
82W FAQ
What was Hims & Hers Health, Inc.’s price range in the past 12 months?
Hims & Hers Health, Inc. lowest stock price was €13.14 and its highest was €65.36 in the past 12 months.
What is Hims & Hers Health, Inc.’s market cap?
Hims & Hers Health, Inc.’s market cap is €3.07B.
When is Hims & Hers Health, Inc.’s upcoming earnings report date?
Hims & Hers Health, Inc.’s upcoming earnings report date is Feb 23, 2026 which is in 3 days.
How were Hims & Hers Health, Inc.’s earnings last quarter?
Hims & Hers Health, Inc. released its earnings results on Nov 03, 2025. The company reported €0.051 earnings per share for the quarter, missing the consensus estimate of €0.08 by -€0.029.
Is Hims & Hers Health, Inc. overvalued?
According to Wall Street analysts Hims & Hers Health, Inc.’s price is currently Undervalued.
Does Hims & Hers Health, Inc. pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
What is Hims & Hers Health, Inc.’s EPS estimate?
Hims & Hers Health, Inc.’s EPS estimate is 0.03.
How many shares outstanding does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc. has 219,270,890 shares outstanding.
What happened to Hims & Hers Health, Inc.’s price movement after its last earnings report?
Hims & Hers Health, Inc. reported an EPS of €0.051 in its last earnings report, missing expectations of €0.08. Following the earnings report the stock price went up 2.041%.
Which hedge fund is a major shareholder of Hims & Hers Health, Inc.?
Currently, no hedge funds are holding shares in DE:82W
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€27.55 (104.50% Upside)
€27.55 (104.50% Upside)
Blogger Sentiment
Bullish
DE:82W Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $512.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.98%
12-Months-Change
Fundamentals
Return on Equity
26.21%
Trailing 12-Months
Asset Growth
270.82%
Trailing 12-Months
Company Description
Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
82W Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a strong performance with significant revenue growth, strategic partnerships, and international expansion. However, there are challenges in gross margins and increased G&A costs. The company's strategy and future outlook remain optimistic.View all DE:82W earnings summaries82W Revenue Breakdown
96.60% Online
3.40% Wholesale
82W Stock 12 Month Forecast
Average Price Target
€27.55
▲(104.50% Upside)
Technical Analysis
Options Prices
Currently, No data available
---